During the 3rd European CAR T-cell Meeting, the ALL Hub spoke to Arnon Nagler, Tel Aviv University, Tel Aviv, IL. We asked, What is new for CAR T-cell therapy for adult patients with ALL?
While acute myeloid leukemia (AML) is more common than ALL in adult patients, the latter carries a much poorer prognosis with recent studies showing a 5-year overall survival rate of only 7–8% in patients with relapsed or refractory disease. Therefore, novel agents and methods for managing these patients are desperately needed.
In this podcast, Arnon Nagler discusses the results from recent clinical trials and the use of bispecific T-cell engager (BiTE) antibodies, such as blinatumomab. He also speaks about how to manage the common side effects of CAR T-cells such as neurotoxicity and cytokine release syndrome.
","author_name":"Scientific Education Support"}